Notably, the IMbrave050 trial is a phase III multicenter randomized study aiming to assess atezolizumab (an antibody against PD-L1) plus bevacizumab (an antibody against vascular endothelial growth factor) versus active surveillance in patients with HCC at a high risk of recurrence following curative resection or ablation. This evidence concerns the gene CD274 and hepatocellular carcinoma.